-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Insiders Who Placed Huge Bets on C-MER Eye Care Holdings Limited (HKG:3309) Earlier This Year Would Be Disappointed With the 8.8% Drop
Insiders Who Placed Huge Bets on C-MER Eye Care Holdings Limited (HKG:3309) Earlier This Year Would Be Disappointed With the 8.8% Drop
The recent price decline of 8.8% in C-MER Eye Care Holdings Limited's (HKG:3309) stock may have disappointed insiders who bought HK$48m worth of shares at an average price of HK$5.26 in the past 12 months. Insiders buy with the expectation to see their investments rise in value over a period of time. However, recent losses have rendered their above investment worth HK$33m which is not ideal.
Although we don't think shareholders should simply follow insider transactions, we would consider it foolish to ignore insider transactions altogether.
See our latest analysis for C-MER Eye Care Holdings
The Last 12 Months Of Insider Transactions At C-MER Eye Care Holdings
In the last twelve months, the biggest single purchase by an insider was when Chairman & CEO Shun Chiu Lam bought HK$48m worth of shares at a price of HK$5.26 per share. That means that even when the share price was higher than HK$3.64 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Shun Chiu Lam was the only individual insider to buy during the last year.
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
SEHK:3309 Insider Trading Volume September 22nd 2022There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Does C-MER Eye Care Holdings Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 1.6% of C-MER Eye Care Holdings shares, worth about HK$70m, according to our data. However, it's possible that insiders might have an indirect interest through a more complex structure. Whilst better than nothing, we're not overly impressed by these holdings.
So What Does This Data Suggest About C-MER Eye Care Holdings Insiders?
There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. Overall we don't see anything to make us think C-MER Eye Care Holdings insiders are doubting the company, and they do own shares. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. In terms of investment risks, we've identified 3 warning signs with C-MER Eye Care Holdings and understanding these should be part of your investment process.
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
最近價格下跌了8.8%,C-mer眼科護理控股有限公司(HKG:3309)股票可能令過去12個月以5.26港元的平均價買入價值4800萬港元的股票的內部人士感到失望。內部人士買入股票的預期是,他們的投資會在一段時間內升值。然而,最近的虧損使他們的上述投資價值3300萬港元,這並不理想。
儘管我們不認為股東應該簡單地追隨內幕交易,但我們認為完全忽視內幕交易是愚蠢的。
查看我們對C-mer Eye Care Holdings的最新分析
C-mer Eye Care Holdings最近12個月的內幕交易
在過去12個月裏,內部人士最大的一筆收購是董事長兼首席執行官林順超以每股5.26港元的價格購買了價值4800萬港元的股票。這意味着,即使股價高於3.64港元(最近的價格),也有內部人士想要購買股票。儘管他們的觀點可能在收購後發生了變化,但這至少表明他們對公司的未來充滿信心。對我們來説,考慮內部人士為股票支付的價格非常重要。看到內部人士支付高於當前股價的價格是令人鼓舞的,因為這表明他們看到了價值,即使是在更高的水平。林順超是去年唯一買入的個人內部人士。
你可以看到過去一年的內幕交易(由公司和個人),如下圖所示。通過點擊下面的圖表,你可以看到每一筆內幕交易的準確細節!
聯交所:3309內幕交易量2022年9月22日內部人士總是在買入大量股票。因此,如果這適合你的風格,你可以逐一檢查每一種庫存,或者你可以看看這個免費公司名單。(提示:內部人士一直在買入這些股票)。
C-mer Eye Care Holdings是否擁有很高的內部人持股?
對於一個普通股股東來説,公司內部人士持有多少股份值得一查。內部人持股比例較高往往會讓公司領導層更加關注股東利益。根據我們的數據,內部人士持有C-mer Eye Care Holdings 1.6%的股份,價值約7000萬港元。然而,內部人士可能會通過更復雜的結構擁有間接利益。雖然總比什麼都沒有好,但我們對這些持股並不是太印象深刻。
那麼,這些數據對C-mer眼科護理控股公司的內部人士有何啟示?
過去三個月沒有發生任何內幕交易--這並不意味着什麼。樂觀的一面是,過去一年的交易令人鼓舞。總體而言,我們沒有看到任何讓我們認為C-mer Eye Care Holdings的內部人士對該公司持懷疑態度的東西,他們確實持有該公司的股份。因此,雖然瞭解內部人士在買入或賣出方面做了什麼是有幫助的,但瞭解一家特定公司面臨的風險也是有幫助的。在投資風險方面,我們已經確定了三個警告信號與C-mer眼科護理控股公司合作,並瞭解這些應該是您投資過程的一部分。
如果你更願意看看另一家公司--一家財務狀況可能更好的公司--那麼不要錯過這一點免費列出了一些有趣的公司,這些公司擁有高股本回報率和低債務。
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前負責公開市場交易和私人處置,但不包括衍生品交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧